Davidson Kempner Capital Management’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

Davidson Kempner Capital Management’s Portfolio BIOT Stock Details BIOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-450,000	Closed	-$4.54M	–	477
2022 Q4	$4.54M	Hold	450,000	–	–	0.09%	194
2022 Q3	$4.46M	Hold	450,000	–	–	0.08%	215
2022 Q2	$4.42M	Hold	450,000	–	–	0.08%	223
2022 Q1	$4.43M	Hold	450,000	–	–	0.06%	247
2021 Q4	$4.42M	Hold	450,000	–	–	0.07%	231
2021 Q3	$4.38M	Buy	450,000 +57,202	+15%	+$554K	0.06%	206
2021 Q2	$3.79M	Buy	+392,798	New	+$3.82M	0.03%	274

Davidson Kempner Capital Management's BIOT Position: Q1 2023 in Review

Davidson Kempner Capital Management sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q1 2023, closing a stake of 450,000 shares — an estimated $4.54M sold.

Davidson Kempner Capital Management first reported a position in BIOT in Q2 2021 and held it in 7 quarters. The position peaked at $4.54M in Q4 2022. 0 funds tracked by Wall St. Rank hold BIOT as of Q1 2023.

Davidson Kempner Capital Management reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Davidson Kempner Capital Management sold 450,000 Biotech Acquisition Company Class A Ordinary Shares shares in Q1 2023, an estimated $4.54M.
Davidson Kempner Capital Management first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q2 2021 and held it in 7 quarters.
Davidson Kempner Capital Management's Biotech Acquisition Company Class A Ordinary Shares position peaked at $4.54M in Q4 2022.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q1 2023.

Based on Davidson Kempner Capital Management's 13F filing for Q1 2023, filed 15 May 2023.